OA10621A - Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin - Google Patents
Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin Download PDFInfo
- Publication number
- OA10621A OA10621A OA70095A OA70095A OA10621A OA 10621 A OA10621 A OA 10621A OA 70095 A OA70095 A OA 70095A OA 70095 A OA70095 A OA 70095A OA 10621 A OA10621 A OA 10621A
- Authority
- OA
- OAPI
- Prior art keywords
- methyl
- isoxazolyl
- thiophene
- sulfonamide
- chloro
- Prior art date
Links
- 108050009340 Endothelin Proteins 0.000 title claims abstract description 144
- 102000002045 Endothelin Human genes 0.000 title claims abstract description 125
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title claims abstract description 114
- 230000000694 effects Effects 0.000 title claims abstract description 70
- 125000002541 furyl group Chemical group 0.000 title claims description 16
- 125000001544 thienyl group Chemical group 0.000 title claims description 13
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 title description 4
- 229940124530 sulfonamide Drugs 0.000 claims abstract description 248
- 238000000034 method Methods 0.000 claims abstract description 111
- 102000005962 receptors Human genes 0.000 claims abstract description 68
- 108020003175 receptors Proteins 0.000 claims abstract description 68
- 150000003456 sulfonamides Chemical class 0.000 claims abstract description 51
- 102000010180 Endothelin receptor Human genes 0.000 claims abstract description 18
- 108050001739 Endothelin receptor Proteins 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 150000002148 esters Chemical class 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 249
- BWJZHYWAXLWLTB-UHFFFAOYSA-N thiophene-3-sulfonamide Chemical compound NS(=O)(=O)C=1C=CSC=1 BWJZHYWAXLWLTB-UHFFFAOYSA-N 0.000 claims description 159
- -1 3lkenyl Chemical group 0.000 claims description 150
- 125000003118 aryl group Chemical group 0.000 claims description 135
- 125000000217 alkyl group Chemical group 0.000 claims description 110
- 239000001257 hydrogen Substances 0.000 claims description 87
- 229910052739 hydrogen Inorganic materials 0.000 claims description 87
- 125000003342 alkenyl group Chemical group 0.000 claims description 70
- 125000000304 alkynyl group Chemical group 0.000 claims description 70
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 claims description 69
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 65
- 125000000623 heterocyclic group Chemical group 0.000 claims description 63
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 61
- 150000002431 hydrogen Chemical group 0.000 claims description 60
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 55
- 125000003545 alkoxy group Chemical group 0.000 claims description 54
- 150000004820 halides Chemical class 0.000 claims description 53
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 46
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 45
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 42
- 125000001424 substituent group Chemical group 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 38
- 230000001404 mediated effect Effects 0.000 claims description 37
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 35
- 125000005605 benzo group Chemical group 0.000 claims description 30
- 125000001188 haloalkyl group Chemical group 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 27
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 23
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 22
- 125000004104 aryloxy group Chemical group 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- 206010020772 Hypertension Diseases 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 125000002577 pseudohalo group Chemical group 0.000 claims description 17
- 206010047139 Vasoconstriction Diseases 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 16
- 230000025033 vasoconstriction Effects 0.000 claims description 16
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 13
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 13
- 125000005843 halogen group Chemical group 0.000 claims description 13
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 10
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 150000001408 amides Chemical class 0.000 claims description 9
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 9
- 230000035939 shock Effects 0.000 claims description 9
- 230000003042 antagnostic effect Effects 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 239000005022 packaging material Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- 125000001769 aryl amino group Chemical group 0.000 claims description 7
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 6
- 125000005110 aryl thio group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- BJVAENLIIOACPY-UHFFFAOYSA-N 1-benzothiophene-3-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=CSC2=C1 BJVAENLIIOACPY-UHFFFAOYSA-N 0.000 claims description 5
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 claims description 5
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 5
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 206010002199 Anaphylactic shock Diseases 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 208000003455 anaphylaxis Diseases 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 125000003106 haloaryl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 3
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- XNTWONAICPPJDM-UHFFFAOYSA-N furan-3-sulfonamide Chemical compound NS(=O)(=O)C=1C=COC=1 XNTWONAICPPJDM-UHFFFAOYSA-N 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000005504 styryl group Chemical group 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- RPGLFLADGRRVLZ-UHFFFAOYSA-N 1-(furan-2-yl)-2-phenylethanone Chemical compound C=1C=COC=1C(=O)CC1=CC=CC=C1 RPGLFLADGRRVLZ-UHFFFAOYSA-N 0.000 claims description 2
- HXMVINSKZVYIDI-UHFFFAOYSA-N 2-phenyl-1-thiophen-2-ylethanone Chemical compound C=1C=CSC=1C(=O)CC1=CC=CC=C1 HXMVINSKZVYIDI-UHFFFAOYSA-N 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- ILZXWYADEVOZKS-UHFFFAOYSA-N [2-(2-phenylethenyl)furan-3-yl] acetate Chemical compound C1=COC(C=CC=2C=CC=CC=2)=C1OC(=O)C ILZXWYADEVOZKS-UHFFFAOYSA-N 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 2
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 6
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- USQCUKQZXOWUDF-YWZLYKJASA-N 6-chloro-n-[(3s)-1-[(2s)-1-(4-methyl-5-oxo-1,4-diazepan-1-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide Chemical compound O=C([C@@H](N1C([C@@H](NS(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1)=O)C)N1CCN(C)C(=O)CC1 USQCUKQZXOWUDF-YWZLYKJASA-N 0.000 claims 1
- 241001280643 Halice Species 0.000 claims 1
- 101000636811 Homo sapiens Neudesin Proteins 0.000 claims 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims 1
- 101000956900 Mesobuthus martensii HMG-CoA reductase inhibitor bumarsin Proteins 0.000 claims 1
- 102100031903 Neudesin Human genes 0.000 claims 1
- 235000011464 Pachycereus pringlei Nutrition 0.000 claims 1
- 240000006939 Pachycereus weberi Species 0.000 claims 1
- 235000011466 Pachycereus weberi Nutrition 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000005154 alkyl sulfonyl amino alkyl group Chemical group 0.000 claims 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims 1
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 1
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000002175 menstrual effect Effects 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 229940099990 ogen Drugs 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 150000003839 salts Chemical class 0.000 abstract description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 450
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 323
- 235000019439 ethyl acetate Nutrition 0.000 description 157
- 239000007787 solid Substances 0.000 description 146
- 229940093499 ethyl acetate Drugs 0.000 description 136
- 239000000243 solution Substances 0.000 description 131
- 239000000203 mixture Substances 0.000 description 109
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 88
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 74
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 70
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 238000000746 purification Methods 0.000 description 58
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 57
- 238000003818 flash chromatography Methods 0.000 description 54
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 52
- 238000006243 chemical reaction Methods 0.000 description 52
- 229910001868 water Inorganic materials 0.000 description 52
- 239000002904 solvent Substances 0.000 description 48
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- 239000003921 oil Substances 0.000 description 45
- 235000019198 oils Nutrition 0.000 description 45
- 238000003756 stirring Methods 0.000 description 42
- 239000012044 organic layer Substances 0.000 description 41
- XCYKKCVEVOZFIL-UHFFFAOYSA-N 4-bromo-3-methyl-1,2-oxazol-5-amine Chemical compound CC1=NOC(N)=C1Br XCYKKCVEVOZFIL-UHFFFAOYSA-N 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 40
- 238000004128 high performance liquid chromatography Methods 0.000 description 40
- 229910000104 sodium hydride Inorganic materials 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 37
- 238000001953 recrystallisation Methods 0.000 description 37
- 229930192474 thiophene Natural products 0.000 description 36
- 239000011541 reaction mixture Substances 0.000 description 34
- 238000004440 column chromatography Methods 0.000 description 31
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 30
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 29
- 102100040611 Endothelin receptor type B Human genes 0.000 description 27
- 101000967299 Homo sapiens Endothelin receptor type B Proteins 0.000 description 27
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 26
- 239000000047 product Substances 0.000 description 26
- 229960001701 chloroform Drugs 0.000 description 25
- 239000012043 crude product Substances 0.000 description 25
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 23
- 238000004587 chromatography analysis Methods 0.000 description 22
- 229940073584 methylene chloride Drugs 0.000 description 22
- 239000000843 powder Substances 0.000 description 22
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 239000003480 eluent Substances 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 229960001866 silicon dioxide Drugs 0.000 description 19
- 235000011121 sodium hydroxide Nutrition 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- 101800004490 Endothelin-1 Proteins 0.000 description 17
- 229940022663 acetate Drugs 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 16
- 102400000686 Endothelin-1 Human genes 0.000 description 15
- 239000005557 antagonist Substances 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 13
- 238000001704 evaporation Methods 0.000 description 13
- 230000008020 evaporation Effects 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- 239000000556 agonist Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 239000012312 sodium hydride Substances 0.000 description 11
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 7
- PYNDWPFZDQONDV-UHFFFAOYSA-N 3,4-dimethyl-1,2-oxazol-5-amine Chemical compound CC1=NOC(N)=C1C PYNDWPFZDQONDV-UHFFFAOYSA-N 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000002308 endothelin receptor antagonist Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 229940083608 sodium hydroxide Drugs 0.000 description 7
- XQULVCXDMBETEF-UHFFFAOYSA-N 1-(5-bromothiophen-2-yl)sulfonylpyrrole Chemical compound S1C(Br)=CC=C1S(=O)(=O)N1C=CC=C1 XQULVCXDMBETEF-UHFFFAOYSA-N 0.000 description 6
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 6
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 229960000443 hydrochloric acid Drugs 0.000 description 6
- 235000011167 hydrochloric acid Nutrition 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000004533 oil dispersion Substances 0.000 description 6
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 6
- 230000006461 physiological response Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 239000005526 vasoconstrictor agent Substances 0.000 description 6
- ITTLWTXFEWOKLP-UHFFFAOYSA-N 3-[(4-bromo-3-methyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxylic acid Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(O)=O)=C1Br ITTLWTXFEWOKLP-UHFFFAOYSA-N 0.000 description 5
- XCMISAPCWHTVNG-UHFFFAOYSA-N 3-bromothiophene Chemical compound BrC=1C=CSC=1 XCMISAPCWHTVNG-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 239000012259 ether extract Substances 0.000 description 5
- IEKOSPNJXYCZHY-UHFFFAOYSA-N furan-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CO1 IEKOSPNJXYCZHY-UHFFFAOYSA-N 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- OHZZTXYKLXZFSZ-UHFFFAOYSA-I manganese(3+) 5,10,15-tris(1-methylpyridin-1-ium-4-yl)-20-(1-methylpyridin-4-ylidene)porphyrin-22-ide pentachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mn+3].C1=CN(C)C=CC1=C1C(C=C2)=NC2=C(C=2C=C[N+](C)=CC=2)C([N-]2)=CC=C2C(C=2C=C[N+](C)=CC=2)=C(C=C2)N=C2C(C=2C=C[N+](C)=CC=2)=C2N=C1C=C2 OHZZTXYKLXZFSZ-UHFFFAOYSA-I 0.000 description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229940001593 sodium carbonate Drugs 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- WYYRQMZTUXFUTC-UHFFFAOYSA-N 1-benzothiophene-3-sulfonyl chloride Chemical compound C1=CC=C2C(S(=O)(=O)Cl)=CSC2=C1 WYYRQMZTUXFUTC-UHFFFAOYSA-N 0.000 description 4
- URFPRAHGGBYNPW-UHFFFAOYSA-N 1-bromo-4-ethylbenzene Chemical compound CCC1=CC=C(Br)C=C1 URFPRAHGGBYNPW-UHFFFAOYSA-N 0.000 description 4
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 108090000387 Endothelin-2 Proteins 0.000 description 4
- 102000003965 Endothelin-2 Human genes 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- MLFJHYIHIKEBTQ-IYRKOGFYSA-N endothelin 2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CNC=N1 MLFJHYIHIKEBTQ-IYRKOGFYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- RHBMVXBGYGIDJN-UHFFFAOYSA-N furan-2-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CO1 RHBMVXBGYGIDJN-UHFFFAOYSA-N 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- MDHYEMXUFSJLGV-UHFFFAOYSA-N phenethyl acetate Chemical compound CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 description 4
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 229960001407 sodium bicarbonate Drugs 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- MBHURWYWZFYDQD-HDUXTRFBSA-N (4r)-4-[[(2r)-2-[[(2s)-2-[[(2r,3s)-2-[[(2s)-2-aminopropanoyl]amino]-3-methylpentanoyl]amino]-4-methylpent-4-enoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-5-oxopentanoic acid Chemical compound C1=CC=C2C(C[C@@H](NC(=O)[C@H](CC(C)=C)NC(=O)[C@H](NC(=O)[C@H](C)N)[C@@H](C)CC)C(=O)N[C@H](CCC(O)=O)C=O)=CNC2=C1 MBHURWYWZFYDQD-HDUXTRFBSA-N 0.000 description 3
- RHFWLPWDOYJEAL-UHFFFAOYSA-N 1,2-oxazol-3-amine Chemical compound NC=1C=CON=1 RHFWLPWDOYJEAL-UHFFFAOYSA-N 0.000 description 3
- MNISARBQEABDRT-UHFFFAOYSA-N 1-(4-propan-2-ylphenyl)pyrrole-2-sulfonic acid Chemical compound C1=CC(C(C)C)=CC=C1N1C(S(O)(=O)=O)=CC=C1 MNISARBQEABDRT-UHFFFAOYSA-N 0.000 description 3
- PMZZGAWQPPABHU-UHFFFAOYSA-N 1-(4-propan-2-ylphenyl)pyrrole-3-sulfonyl chloride Chemical compound C1=CC(C(C)C)=CC=C1N1C=C(S(Cl)(=O)=O)C=C1 PMZZGAWQPPABHU-UHFFFAOYSA-N 0.000 description 3
- CPZSYEVVCYQNBE-UHFFFAOYSA-N 1-[3-(1,3-benzodioxol-5-yl)thiophen-2-yl]sulfonylpyrrole Chemical compound S1C=CC(C=2C=C3OCOC3=CC=2)=C1S(=O)(=O)N1C=CC=C1 CPZSYEVVCYQNBE-UHFFFAOYSA-N 0.000 description 3
- RWCKBBSBRTUUHR-UHFFFAOYSA-N 1-benzofuran-2-sulfonyl chloride Chemical compound C1=CC=C2OC(S(=O)(=O)Cl)=CC2=C1 RWCKBBSBRTUUHR-UHFFFAOYSA-N 0.000 description 3
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 3
- VPGIYLLXBOUILV-UHFFFAOYSA-N 2-benzylthiophene Chemical compound C=1C=CC=CC=1CC1=CC=CS1 VPGIYLLXBOUILV-UHFFFAOYSA-N 0.000 description 3
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 description 3
- SYCPGPBCEDENBL-UHFFFAOYSA-N 3-[(4-bromo-3-methyl-1,2-oxazol-5-yl)sulfamoyl]-n-(3-methoxyphenyl)thiophene-2-carboxamide Chemical compound COC1=CC=CC(NC(=O)C2=C(C=CS2)S(=O)(=O)NC2=C(C(C)=NO2)Br)=C1 SYCPGPBCEDENBL-UHFFFAOYSA-N 0.000 description 3
- FSUWQETZHKACGA-UHFFFAOYSA-N 3-[(4-bromo-3-methyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxamide Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(N)=O)=C1Br FSUWQETZHKACGA-UHFFFAOYSA-N 0.000 description 3
- DXSHUWUDKNEGFS-UHFFFAOYSA-N 3-phenoxythiophene Chemical compound C=1C=CC=CC=1OC=1C=CSC=1 DXSHUWUDKNEGFS-UHFFFAOYSA-N 0.000 description 3
- JVJQBODRROTGJA-UHFFFAOYSA-N 3-phenoxythiophene-2-sulfonyl chloride Chemical compound S1C=CC(OC=2C=CC=CC=2)=C1S(=O)(=O)Cl JVJQBODRROTGJA-UHFFFAOYSA-N 0.000 description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N 4-Ethylbenzaldehyde Chemical compound CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- QMZMMMMDQVQCHL-UHFFFAOYSA-N 4-chloro-3-methyl-1,2-oxazol-5-amine Chemical compound CC1=NOC(N)=C1Cl QMZMMMMDQVQCHL-UHFFFAOYSA-N 0.000 description 3
- WGYBIEOLAFYDEC-UHFFFAOYSA-N 5-bromothiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)S1 WGYBIEOLAFYDEC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 3
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 3
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 150000001649 bromium compounds Chemical group 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 3
- 150000001805 chlorine compounds Chemical group 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 108010017327 cyclo(glutamyl-alanyl-isoleucyl-leucyl-tryptophyl) Proteins 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- UBIJTWDKTYCPMQ-UHFFFAOYSA-N hexachlorophosphazene Chemical compound ClP1(Cl)=NP(Cl)(Cl)=NP(Cl)(Cl)=N1 UBIJTWDKTYCPMQ-UHFFFAOYSA-N 0.000 description 3
- 150000004678 hydrides Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 3
- DDTRXTBMCRLKHP-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-1-(4-propan-2-ylphenyl)pyrrole-3-sulfonamide Chemical compound C1=CC(C(C)C)=CC=C1N1C=C(S(=O)(=O)NC2=C(C(C)=NO2)Br)C=C1 DDTRXTBMCRLKHP-UHFFFAOYSA-N 0.000 description 3
- SVMURQKJABFKNC-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-(2-methylphenyl)thiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC(=CC=2)C=2C(=CC=CC=2)C)=C1Br SVMURQKJABFKNC-UHFFFAOYSA-N 0.000 description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- CHXZRHMQQRUVHF-UHFFFAOYSA-N thiophene A Natural products CC#CC1=CC=C(C#CC#CC=C)S1 CHXZRHMQQRUVHF-UHFFFAOYSA-N 0.000 description 3
- YSPWSQNKRBSICH-UHFFFAOYSA-N thiophene-3-sulfonyl chloride Chemical compound ClS(=O)(=O)C=1C=CSC=1 YSPWSQNKRBSICH-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 2
- WLCGYIWOKVWFLB-UHFFFAOYSA-N (4-propylphenyl)boronic acid Chemical compound CCCC1=CC=C(B(O)O)C=C1 WLCGYIWOKVWFLB-UHFFFAOYSA-N 0.000 description 2
- LWPRPZFBYSLSLS-UHFFFAOYSA-N 1,3-benzodioxol-5-yl 3-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxylate Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)OC=2C=C3OCOC3=CC=2)=C1C LWPRPZFBYSLSLS-UHFFFAOYSA-N 0.000 description 2
- JBQRAWXTTIKPRD-UHFFFAOYSA-N 1,3-benzodioxol-5-yl 3-[(4-chloro-3-methyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxylate Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)OC=2C=C3OCOC3=CC=2)=C1Cl JBQRAWXTTIKPRD-UHFFFAOYSA-N 0.000 description 2
- HYJQWMUBCRPGDS-UHFFFAOYSA-N 1,3-thiazole-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=NC=CS1 HYJQWMUBCRPGDS-UHFFFAOYSA-N 0.000 description 2
- NMAFKIONZPVOHK-UHFFFAOYSA-N 1-(4-propan-2-ylphenyl)pyrrole Chemical compound C1=CC(C(C)C)=CC=C1N1C=CC=C1 NMAFKIONZPVOHK-UHFFFAOYSA-N 0.000 description 2
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N 2,5-dimethylfuran Chemical compound CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- GEBAVJXLKVTPEZ-UHFFFAOYSA-N 2-(1,3-benzodioxole-5-carbonyl)-n-(4-bromo-3-methyl-1,2-oxazol-5-yl)thiophene-3-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)C=2C=C3OCOC3=CC=2)=C1Br GEBAVJXLKVTPEZ-UHFFFAOYSA-N 0.000 description 2
- GQMRELKVGJWCJV-UHFFFAOYSA-N 2-(1-thiophen-3-ylcyclohexa-2,4-dien-1-yl)ethyl acetate Chemical compound C1=CSC=C1C1(CCOC(=O)C)CC=CC=C1 GQMRELKVGJWCJV-UHFFFAOYSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical compound COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 2
- LXGVDSWNNGBJEJ-UHFFFAOYSA-N 2-[(3,4,5-trimethoxyphenyl)methyl]-1-benzothiophene-3-sulfonyl chloride Chemical compound COC1=C(OC)C(OC)=CC(CC2=C(C3=CC=CC=C3S2)S(Cl)(=O)=O)=C1 LXGVDSWNNGBJEJ-UHFFFAOYSA-N 0.000 description 2
- WPZUCXCXTPQEHO-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-1-benzothiophene-3-sulfonyl chloride Chemical compound C1=CC(Cl)=CC=C1CC1=C(S(Cl)(=O)=O)C2=CC=CC=C2S1 WPZUCXCXTPQEHO-UHFFFAOYSA-N 0.000 description 2
- ABYOCSACUMULHJ-UHFFFAOYSA-N 2-[(4-ethylphenyl)methyl]-1-benzothiophene-3-sulfonyl chloride Chemical compound C1=CC(CC)=CC=C1CC1=C(S(Cl)(=O)=O)C2=CC=CC=C2S1 ABYOCSACUMULHJ-UHFFFAOYSA-N 0.000 description 2
- YDANFNUATFWKJU-UHFFFAOYSA-N 2-butyl-1-benzothiophene Chemical compound C1=CC=C2SC(CCCC)=CC2=C1 YDANFNUATFWKJU-UHFFFAOYSA-N 0.000 description 2
- OPIFKAGXIKNRIR-UHFFFAOYSA-N 2-methyl-1-benzothiophene-3-sulfonyl chloride Chemical compound C1=CC=C2C(S(Cl)(=O)=O)=C(C)SC2=C1 OPIFKAGXIKNRIR-UHFFFAOYSA-N 0.000 description 2
- IBJARYHUXSJWRZ-UHFFFAOYSA-N 2-propyl-1-benzothiophene Chemical compound C1=CC=C2SC(CCC)=CC2=C1 IBJARYHUXSJWRZ-UHFFFAOYSA-N 0.000 description 2
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 2
- BFHRUBBQSOEBHK-UHFFFAOYSA-N 3-[(4-bromo-3-methyl-1,2-oxazol-5-yl)sulfamoyl]-n-(2-hydroxyphenyl)thiophene-2-carboxamide Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)NC=2C(=CC=CC=2)O)=C1Br BFHRUBBQSOEBHK-UHFFFAOYSA-N 0.000 description 2
- XTLWXRWZKDAMBY-UHFFFAOYSA-N 3-benzyl-n-(4-bromo-3-methyl-1,2-oxazol-5-yl)thiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C2=C(C=CS2)CC=2C=CC=CC=2)=C1Br XTLWXRWZKDAMBY-UHFFFAOYSA-N 0.000 description 2
- HQSWHMYDUWHRIX-UHFFFAOYSA-N 3-bromo-2-phenylthiophene Chemical compound C1=CSC(C=2C=CC=CC=2)=C1Br HQSWHMYDUWHRIX-UHFFFAOYSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- HLKHDXRCRNEXSF-UHFFFAOYSA-N 3-methoxythiophene-2-sulfonyl chloride Chemical compound COC=1C=CSC=1S(Cl)(=O)=O HLKHDXRCRNEXSF-UHFFFAOYSA-N 0.000 description 2
- MFVWPGCVRGBTSD-UHFFFAOYSA-N 4-(2-phenylethyl)thiophene-2-sulfonyl chloride Chemical compound S1C(S(=O)(=O)Cl)=CC(CCC=2C=CC=CC=2)=C1 MFVWPGCVRGBTSD-UHFFFAOYSA-N 0.000 description 2
- HRXZRAXKKNUKRF-UHFFFAOYSA-N 4-ethylaniline Chemical compound CCC1=CC=C(N)C=C1 HRXZRAXKKNUKRF-UHFFFAOYSA-N 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- JCOGEEUZNXSGIT-UHFFFAOYSA-N 4-phenylthiophene-2-sulfonyl chloride Chemical compound S1C(S(=O)(=O)Cl)=CC(C=2C=CC=CC=2)=C1 JCOGEEUZNXSGIT-UHFFFAOYSA-N 0.000 description 2
- BSASHGINZZGQLY-UHFFFAOYSA-N 5-(2-formylphenyl)-n-(3-methyl-1,2-oxazol-5-yl)thiophene-2-sulfonamide Chemical compound O1N=C(C)C=C1NS(=O)(=O)C1=CC=C(C=2C(=CC=CC=2)C=O)S1 BSASHGINZZGQLY-UHFFFAOYSA-N 0.000 description 2
- YEVZOGCQROAOCT-UHFFFAOYSA-N 5-(2-methoxyphenyl)thiophene-2-sulfonyl chloride Chemical compound COC1=CC=CC=C1C1=CC=C(S(Cl)(=O)=O)S1 YEVZOGCQROAOCT-UHFFFAOYSA-N 0.000 description 2
- PXGSLNHIMXKHJW-UHFFFAOYSA-N 5-(3-methoxyphenyl)thiophene-2-sulfonyl chloride Chemical compound COC1=CC=CC(C=2SC(=CC=2)S(Cl)(=O)=O)=C1 PXGSLNHIMXKHJW-UHFFFAOYSA-N 0.000 description 2
- QUQWGUVDPICBES-UHFFFAOYSA-N 5-(4-ethylphenyl)thiophene-2-sulfonyl chloride Chemical compound C1=CC(CC)=CC=C1C1=CC=C(S(Cl)(=O)=O)S1 QUQWGUVDPICBES-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 101100240522 Caenorhabditis elegans nhr-18 gene Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 206010011416 Croup infectious Diseases 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010072844 Endothelin-3 Proteins 0.000 description 2
- 102100029109 Endothelin-3 Human genes 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 229910017974 NH40H Inorganic materials 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010030043 Ocular hypertension Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- DMVOXQPQNTYEKQ-UHFFFAOYSA-N biphenyl-4-amine Chemical compound C1=CC(N)=CC=C1C1=CC=CC=C1 DMVOXQPQNTYEKQ-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 230000007883 bronchodilation Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- ZGOVYTPSWMLYOF-QEADGSHQSA-N chembl1790180 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@H](CCC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)[C@H](C)O)=O)NC(=O)[C@@H]([C@@H](C)O)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZGOVYTPSWMLYOF-QEADGSHQSA-N 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 201000010549 croup Diseases 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- PJVJBDAUWILEOG-UHFFFAOYSA-N methyl 3-chlorosulfonylthiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1S(Cl)(=O)=O PJVJBDAUWILEOG-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- JNCMNPQOJWALQJ-UHFFFAOYSA-N n-(1,3-benzodioxol-5-yl)-3-[(4-bromo-3-methyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxamide Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)NC=2C=C3OCOC3=CC=2)=C1Br JNCMNPQOJWALQJ-UHFFFAOYSA-N 0.000 description 2
- SNIWYFFQCHGBSF-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-1,3-thiazole-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC=CN=2)=C1Br SNIWYFFQCHGBSF-UHFFFAOYSA-N 0.000 description 2
- CWFKSFPROWKTOG-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-4-(2-phenylethyl)thiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC=C(CCC=3C=CC=CC=3)C=2)=C1Br CWFKSFPROWKTOG-UHFFFAOYSA-N 0.000 description 2
- YRBRRBLBZBUYBX-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-(2-methylfuran-3-yl)thiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC(=CC=2)C2=C(OC=C2)C)=C1Br YRBRRBLBZBUYBX-UHFFFAOYSA-N 0.000 description 2
- KTDKDFUQRKEJCE-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-(4-methoxyphenyl)thiophene-2-sulfonamide Chemical compound C1=CC(OC)=CC=C1C1=CC=C(S(=O)(=O)NC2=C(C(C)=NO2)Br)S1 KTDKDFUQRKEJCE-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229940081310 piperonal Drugs 0.000 description 2
- VDVJGIYXDVPQLP-UHFFFAOYSA-N piperonylic acid Chemical compound OC(=O)C1=CC=C2OCOC2=C1 VDVJGIYXDVPQLP-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 2
- ZMCBYSBVJIMENC-UHFFFAOYSA-N tricaine Chemical compound CCOC(=O)C1=CC=CC(N)=C1 ZMCBYSBVJIMENC-UHFFFAOYSA-N 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- 238000007514 turning Methods 0.000 description 2
- 210000001177 vas deferen Anatomy 0.000 description 2
- 230000002227 vasoactive effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- HDWUZVCGADZBAK-UHFFFAOYSA-N (1-thiophen-2-ylcyclohexa-2,4-dien-1-yl)methyl acetate Chemical compound C=1C=CSC=1C1(COC(=O)C)CC=CC=C1 HDWUZVCGADZBAK-UHFFFAOYSA-N 0.000 description 1
- DGUWACLYDSWXRZ-UHFFFAOYSA-N (2-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C=O DGUWACLYDSWXRZ-UHFFFAOYSA-N 0.000 description 1
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 1
- BJQCPCFFYBKRLM-UHFFFAOYSA-N (3-methylphenyl)boronic acid Chemical compound CC1=CC=CC(B(O)O)=C1 BJQCPCFFYBKRLM-UHFFFAOYSA-N 0.000 description 1
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- RZCPLOMUUCFPQA-UHFFFAOYSA-N (4-ethylphenyl)boronic acid Chemical compound CCC1=CC=C(B(O)O)C=C1 RZCPLOMUUCFPQA-UHFFFAOYSA-N 0.000 description 1
- IAEUFBDMVKQCLU-UHFFFAOYSA-N (4-propan-2-ylphenyl)boronic acid Chemical compound CC(C)C1=CC=C(B(O)O)C=C1 IAEUFBDMVKQCLU-UHFFFAOYSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- IAXWZYXUKABJAN-UHFFFAOYSA-N 1,2-oxazol-5-amine Chemical group NC1=CC=NO1 IAXWZYXUKABJAN-UHFFFAOYSA-N 0.000 description 1
- XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 1
- JQBUPYPWHBIMNX-UHFFFAOYSA-N 1,3-benzodioxol-5-yl 3-[(4-bromo-3-methyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxylate Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)OC=2C=C3OCOC3=CC=2)=C1Br JQBUPYPWHBIMNX-UHFFFAOYSA-N 0.000 description 1
- CMHPUBKZZPSUIQ-UHFFFAOYSA-N 1,3-benzodioxol-5-ylboronic acid Chemical compound OB(O)C1=CC=C2OCOC2=C1 CMHPUBKZZPSUIQ-UHFFFAOYSA-N 0.000 description 1
- NBOOZXVYXHATOW-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-ylmethyl)piperazine Chemical compound C=1C=C2OCOC2=CC=1CN1CCNCC1 NBOOZXVYXHATOW-UHFFFAOYSA-N 0.000 description 1
- UVKZWBMMDITQEZ-UHFFFAOYSA-N 1-(3-bromothiophen-2-yl)sulfonylpyrrole Chemical compound C1=CSC(S(=O)(=O)N2C=CC=C2)=C1Br UVKZWBMMDITQEZ-UHFFFAOYSA-N 0.000 description 1
- QMJPRFOPWMHWSP-UHFFFAOYSA-N 1-(4-propan-2-ylphenyl)pyrrole-2-sulfonamide Chemical compound C(C)(C)C1=CC=C(C=C1)N1C(=CC=C1)S(=O)(=O)N QMJPRFOPWMHWSP-UHFFFAOYSA-N 0.000 description 1
- FNQDZDJIHXGTNU-UHFFFAOYSA-N 1-(4-propan-2-ylphenyl)pyrrole-2-sulfonyl chloride Chemical compound C1=CC(C(C)C)=CC=C1N1C(S(Cl)(=O)=O)=CC=C1 FNQDZDJIHXGTNU-UHFFFAOYSA-N 0.000 description 1
- HTWGCYVUOOLXQN-UHFFFAOYSA-N 1-(5-thiophen-3-ylthiophen-2-yl)sulfonylpyrrole Chemical compound C1=CC=CN1S(=O)(=O)C(S1)=CC=C1C=1C=CSC=1 HTWGCYVUOOLXQN-UHFFFAOYSA-N 0.000 description 1
- SQZCAOHYQSOZCE-UHFFFAOYSA-N 1-(diaminomethylidene)-2-(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1N=C(N)N=C(N)N SQZCAOHYQSOZCE-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- PILMDYMSGQSZFK-UHFFFAOYSA-N 1-[2-(bromomethyl)thiophen-3-yl]sulfonylpyrrole Chemical compound S1C=CC(S(=O)(=O)N2C=CC=C2)=C1CBr PILMDYMSGQSZFK-UHFFFAOYSA-N 0.000 description 1
- DTIXGJFQIXIQMU-UHFFFAOYSA-N 1-[5-(3,3-dimethylbut-1-ynyl)thiophen-2-yl]sulfonylpyrrole Chemical compound S1C(C#CC(C)(C)C)=CC=C1S(=O)(=O)N1C=CC=C1 DTIXGJFQIXIQMU-UHFFFAOYSA-N 0.000 description 1
- NSYOIALJZFSAFH-UHFFFAOYSA-N 1-[5-(4-ethylphenyl)thiophen-2-yl]sulfonylpyrrole Chemical compound C1=CC(CC)=CC=C1C1=CC=C(S(=O)(=O)N2C=CC=C2)S1 NSYOIALJZFSAFH-UHFFFAOYSA-N 0.000 description 1
- WDTLTRMYMKJZJV-UHFFFAOYSA-N 1-[5-(4-methylphenyl)thiophen-2-yl]sulfonylpyrrole Chemical compound C1=CC(C)=CC=C1C1=CC=C(S(=O)(=O)N2C=CC=C2)S1 WDTLTRMYMKJZJV-UHFFFAOYSA-N 0.000 description 1
- HEWGKWLASLBFNU-UHFFFAOYSA-N 1-[5-(4-propylphenyl)thiophen-2-yl]sulfonylpyrrole Chemical compound C1=CC(CCC)=CC=C1C1=CC=C(S(=O)(=O)N2C=CC=C2)S1 HEWGKWLASLBFNU-UHFFFAOYSA-N 0.000 description 1
- CFJTWVKKQWCVHZ-UHFFFAOYSA-N 1-[5-[4-(trifluoromethyl)phenyl]thiophen-2-yl]sulfonylpyrrole Chemical compound C1=CC(C(F)(F)F)=CC=C1C1=CC=C(S(=O)(=O)N2C=CC=C2)S1 CFJTWVKKQWCVHZ-UHFFFAOYSA-N 0.000 description 1
- FKIIVBOPAHICHQ-UHFFFAOYSA-N 1-benzothiophene-2-sulfonyl chloride Chemical compound C1=CC=C2SC(S(=O)(=O)Cl)=CC2=C1 FKIIVBOPAHICHQ-UHFFFAOYSA-N 0.000 description 1
- PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
- UCCUXODGPMAHRL-UHFFFAOYSA-N 1-bromo-4-iodobenzene Chemical compound BrC1=CC=C(I)C=C1 UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- RYMYQAMZUWJAEO-UHFFFAOYSA-N 1h-indole-2-sulfonamide Chemical class C1=CC=C2NC(S(=O)(=O)N)=CC2=C1 RYMYQAMZUWJAEO-UHFFFAOYSA-N 0.000 description 1
- USZKOIUIZMUMSE-UHFFFAOYSA-N 1h-pyrrole-2-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN1 USZKOIUIZMUMSE-UHFFFAOYSA-N 0.000 description 1
- OHZAHWOAMVVGEL-UHFFFAOYSA-N 2,2'-bithiophene Chemical compound C1=CSC(C=2SC=CC=2)=C1 OHZAHWOAMVVGEL-UHFFFAOYSA-N 0.000 description 1
- PIXAQZAVANAGLE-UHFFFAOYSA-N 2,5-dimethylfuran-3-sulfonyl chloride Chemical compound CC1=CC(S(Cl)(=O)=O)=C(C)O1 PIXAQZAVANAGLE-UHFFFAOYSA-N 0.000 description 1
- ZQPBOYASBNAXOZ-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)acetonitrile Chemical compound N#CCC1=CC=C2OCOC2=C1 ZQPBOYASBNAXOZ-UHFFFAOYSA-N 0.000 description 1
- LFJWGKAUSUIRQH-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-ylmethyl)-n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-1-benzothiophene-3-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C3=CC=CC=C3SC=2CC=2C=C3OCOC3=CC=2)=C1Br LFJWGKAUSUIRQH-UHFFFAOYSA-N 0.000 description 1
- KZEXTKXVAVEOQM-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-ylmethyl)thiophene-3-sulfonyl chloride Chemical compound C1=CSC(CC=2C=C3OCOC3=CC=2)=C1S(=O)(=O)Cl KZEXTKXVAVEOQM-UHFFFAOYSA-N 0.000 description 1
- MXPZKSOVGFZLSQ-UHFFFAOYSA-N 2-(2-methylphenyl)thiophene Chemical compound CC1=CC=CC=C1C1=CC=CS1 MXPZKSOVGFZLSQ-UHFFFAOYSA-N 0.000 description 1
- ACLYMWAQSAEILP-UHFFFAOYSA-N 2-(3-ethoxy-5-methoxy-4-methylsulfanylphenyl)ethanamine Chemical compound CCOC1=CC(CCN)=CC(OC)=C1SC ACLYMWAQSAEILP-UHFFFAOYSA-N 0.000 description 1
- SMKMXVCNNASZEB-UHFFFAOYSA-N 2-(3-methylphenyl)thiophene Chemical compound CC1=CC=CC(C=2SC=CC=2)=C1 SMKMXVCNNASZEB-UHFFFAOYSA-N 0.000 description 1
- YFXDUXSCNGJSKQ-UHFFFAOYSA-N 2-(phenylmethoxymethyl)thiophene Chemical compound C=1C=CSC=1COCC1=CC=CC=C1 YFXDUXSCNGJSKQ-UHFFFAOYSA-N 0.000 description 1
- LUEBTNSSTIFNMG-UHFFFAOYSA-N 2-[(2-methoxyphenyl)methyl]-1-benzothiophene Chemical compound COC1=CC=CC=C1CC1=CC2=CC=CC=C2S1 LUEBTNSSTIFNMG-UHFFFAOYSA-N 0.000 description 1
- AKMMTSCMLVACMV-UHFFFAOYSA-N 2-[(2-methoxyphenyl)methyl]-1-benzothiophene-3-sulfonyl chloride Chemical compound COC1=CC=CC=C1CC1=C(S(Cl)(=O)=O)C2=CC=CC=C2S1 AKMMTSCMLVACMV-UHFFFAOYSA-N 0.000 description 1
- LSLAEUKIOXJONR-UHFFFAOYSA-N 2-[(3,4,5-trimethoxyphenyl)methyl]-1-benzothiophene Chemical compound COC1=C(OC)C(OC)=CC(CC=2SC3=CC=CC=C3C=2)=C1 LSLAEUKIOXJONR-UHFFFAOYSA-N 0.000 description 1
- ABWOKEFUDJPLRJ-UHFFFAOYSA-N 2-[(3,4-dimethoxyphenyl)methyl]-1-benzothiophene Chemical compound C1=C(OC)C(OC)=CC=C1CC1=CC2=CC=CC=C2S1 ABWOKEFUDJPLRJ-UHFFFAOYSA-N 0.000 description 1
- CDKJIIYEAWUIJN-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-1-benzothiophene Chemical compound C1=CC(Cl)=CC=C1CC1=CC2=CC=CC=C2S1 CDKJIIYEAWUIJN-UHFFFAOYSA-N 0.000 description 1
- CABSADOZTDAHCA-UHFFFAOYSA-N 2-[(4-ethylphenyl)methyl]-1-benzothiophene Chemical compound C1=CC(CC)=CC=C1CC1=CC2=CC=CC=C2S1 CABSADOZTDAHCA-UHFFFAOYSA-N 0.000 description 1
- MBZRSMYFGWYSRU-UHFFFAOYSA-N 2-[2-(1,3-benzodioxol-5-yl)ethyl]-n-(4-bromo-3-methyl-1,2-oxazol-5-yl)thiophene-3-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)CCC=2C=C3OCOC3=CC=2)=C1Br MBZRSMYFGWYSRU-UHFFFAOYSA-N 0.000 description 1
- VJPJTCJCYMJKQW-UHFFFAOYSA-N 2-[[4-(dimethylamino)phenyl]methyl]-1-benzothiophene-3-sulfonyl chloride Chemical compound C1=CC(N(C)C)=CC=C1CC1=C(S(Cl)(=O)=O)C2=CC=CC=C2S1 VJPJTCJCYMJKQW-UHFFFAOYSA-N 0.000 description 1
- LTCUHVWRCHFODT-UHFFFAOYSA-N 2-benzyl-1-benzothiophene Chemical compound C=1C2=CC=CC=C2SC=1CC1=CC=CC=C1.C=1C2=CC=CC=C2SC=1CC1=CC=CC=C1 LTCUHVWRCHFODT-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- OMOAIGVIYUXYAU-UHFFFAOYSA-N 2-bromo-5-thiophen-2-ylthiophene Chemical compound S1C(Br)=CC=C1C1=CC=CS1 OMOAIGVIYUXYAU-UHFFFAOYSA-N 0.000 description 1
- KJHYAEZMOHLVCH-UHFFFAOYSA-N 2-ethyl-1-benzofuran Chemical compound C1=CC=C2OC(CC)=CC2=C1 KJHYAEZMOHLVCH-UHFFFAOYSA-N 0.000 description 1
- WRXLVICCHCDVNC-UHFFFAOYSA-N 2-ethyl-1-benzofuran-3-sulfonyl chloride Chemical compound C1=CC=C2C(S(Cl)(=O)=O)=C(CC)OC2=C1 WRXLVICCHCDVNC-UHFFFAOYSA-N 0.000 description 1
- JAABUGUCYZQMID-UHFFFAOYSA-N 2-ethyl-1-benzothiophene Chemical compound C1=CC=C2SC(CC)=CC2=C1 JAABUGUCYZQMID-UHFFFAOYSA-N 0.000 description 1
- FFDCYBDKLIDPIL-UHFFFAOYSA-N 2-ethyl-1-benzothiophene-3-sulfonyl chloride Chemical compound C1=CC=C2C(S(Cl)(=O)=O)=C(CC)SC2=C1 FFDCYBDKLIDPIL-UHFFFAOYSA-N 0.000 description 1
- FUHSVKSNUCZRQQ-UHFFFAOYSA-N 2-ethyl-5-methyl-1-benzothiophene Chemical compound CC1=CC=C2SC(CC)=CC2=C1 FUHSVKSNUCZRQQ-UHFFFAOYSA-N 0.000 description 1
- FPVKPNZVRZUDMQ-UHFFFAOYSA-N 2-ethyl-5-methyl-1-benzothiophene-3-sulfonyl chloride Chemical compound C1=C(C)C=C2C(S(Cl)(=O)=O)=C(CC)SC2=C1 FPVKPNZVRZUDMQ-UHFFFAOYSA-N 0.000 description 1
- 125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
- BLZKSRBAQDZAIX-UHFFFAOYSA-N 2-methyl-1-benzothiophene Chemical compound C1=CC=C2SC(C)=CC2=C1 BLZKSRBAQDZAIX-UHFFFAOYSA-N 0.000 description 1
- YFUATKCSPOVJFZ-UHFFFAOYSA-N 2-methyl-1-benzothiophene-3-sulfonamide Chemical compound C1=CC=C2C(S(N)(=O)=O)=C(C)SC2=C1 YFUATKCSPOVJFZ-UHFFFAOYSA-N 0.000 description 1
- GCXNJAXHHFZVIM-UHFFFAOYSA-N 2-phenylfuran Chemical compound C1=COC(C=2C=CC=CC=2)=C1 GCXNJAXHHFZVIM-UHFFFAOYSA-N 0.000 description 1
- KOLRDJDHOMTWFK-UHFFFAOYSA-N 2-phenylsulfanylfuran Chemical compound C=1C=CC=CC=1SC1=CC=CO1 KOLRDJDHOMTWFK-UHFFFAOYSA-N 0.000 description 1
- PJRGDKFLFAYRBV-UHFFFAOYSA-N 2-phenylthiophene Chemical compound C1=CSC(C=2C=CC=CC=2)=C1 PJRGDKFLFAYRBV-UHFFFAOYSA-N 0.000 description 1
- HWTCQMPLZXWABG-UHFFFAOYSA-N 2-phenylthiophene-3-sulfonyl chloride Chemical compound C1=CSC(C=2C=CC=CC=2)=C1S(=O)(=O)Cl HWTCQMPLZXWABG-UHFFFAOYSA-N 0.000 description 1
- KVWNNMYVLSLNSH-UHFFFAOYSA-N 2-propyl-1-benzothiophene-3-sulfonyl chloride Chemical compound C1=CC=C2C(S(Cl)(=O)=O)=C(CCC)SC2=C1.C1=CC=C2C(S(Cl)(=O)=O)=C(CCC)SC2=C1 KVWNNMYVLSLNSH-UHFFFAOYSA-N 0.000 description 1
- FLWBORXFXWJBBE-UHFFFAOYSA-N 2-propyl-1-benzothiophene-3-sulfonyl chloride Chemical compound C1=CC=C2C(S(Cl)(=O)=O)=C(CCC)SC2=C1 FLWBORXFXWJBBE-UHFFFAOYSA-N 0.000 description 1
- ICXIVBYQRNOIJJ-UHFFFAOYSA-N 2-tert-butylbenzenesulfonyl chloride Chemical compound CC(C)(C)C1=CC=CC=C1S(Cl)(=O)=O ICXIVBYQRNOIJJ-UHFFFAOYSA-N 0.000 description 1
- NWYUIYYDNDZXBK-UHFFFAOYSA-N 3,4-dibromo-2,5-dimethylthiophene Chemical compound CC=1SC(C)=C(Br)C=1Br NWYUIYYDNDZXBK-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- AKUSZFPCJFNRSZ-UHFFFAOYSA-N 3,4-dimethyl-1,2-oxazole Chemical compound CC1=CON=C1C AKUSZFPCJFNRSZ-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- QWKLKIJBNKFNLT-UHFFFAOYSA-N 3-(2-phenylethyl)thiophene-2-sulfonyl chloride Chemical compound S1C=CC(CCC=2C=CC=CC=2)=C1S(=O)(=O)Cl QWKLKIJBNKFNLT-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical group N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- LAOUJLCAFJDXFP-UHFFFAOYSA-N 3-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxylic acid Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(O)=O)=C1C LAOUJLCAFJDXFP-UHFFFAOYSA-N 0.000 description 1
- YXXNMIOJLNDCNQ-UHFFFAOYSA-N 3-[(3-bromo-4-methyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxylic acid Chemical compound BrC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(O)=O)=C1C YXXNMIOJLNDCNQ-UHFFFAOYSA-N 0.000 description 1
- VMSGLMJNCOIKRS-UHFFFAOYSA-N 3-[(4-bromo-3-methyl-1,2-oxazol-5-yl)sulfamoyl]-n-(4-butan-2-ylphenyl)thiophene-2-carboxamide Chemical compound C1=CC(C(C)CC)=CC=C1NC(=O)C1=C(S(=O)(=O)NC2=C(C(C)=NO2)Br)C=CS1 VMSGLMJNCOIKRS-UHFFFAOYSA-N 0.000 description 1
- KVRTURHINFWHJV-UHFFFAOYSA-N 3-[(4-bromo-3-methyl-1,2-oxazol-5-yl)sulfamoyl]-n-(4-ethylphenyl)thiophene-2-carboxamide Chemical compound C1=CC(CC)=CC=C1NC(=O)C1=C(S(=O)(=O)NC2=C(C(C)=NO2)Br)C=CS1 KVRTURHINFWHJV-UHFFFAOYSA-N 0.000 description 1
- GQNVKBUSESBTBX-UHFFFAOYSA-N 3-[(4-bromo-3-methyl-1,2-oxazol-5-yl)sulfamoyl]-n-(4-methoxyphenyl)thiophene-2-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1=C(S(=O)(=O)NC2=C(C(C)=NO2)Br)C=CS1 GQNVKBUSESBTBX-UHFFFAOYSA-N 0.000 description 1
- BFHXYQAPYRDEDW-UHFFFAOYSA-N 3-[(4-chloro-3-methyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxylic acid Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(O)=O)=C1Cl BFHXYQAPYRDEDW-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- CWLKGDAVCFYWJK-UHFFFAOYSA-N 3-aminophenol Chemical compound NC1=CC=CC(O)=C1 CWLKGDAVCFYWJK-UHFFFAOYSA-N 0.000 description 1
- 229940018563 3-aminophenol Drugs 0.000 description 1
- KXNZPBKGKGYWGF-UHFFFAOYSA-N 3-benzylthiophene Chemical compound C=1C=CC=CC=1CC=1C=CSC=1.C=1C=CC=CC=1CC=1C=CSC=1 KXNZPBKGKGYWGF-UHFFFAOYSA-N 0.000 description 1
- QNIZTJWJJFGIDS-UHFFFAOYSA-N 3-benzylthiophene Chemical compound C=1C=CC=CC=1CC=1C=CSC=1 QNIZTJWJJFGIDS-UHFFFAOYSA-N 0.000 description 1
- BEWITPGTUWHPDN-UHFFFAOYSA-N 3-benzylthiophene-2-sulfonyl chloride Chemical compound S1C=CC(CC=2C=CC=CC=2)=C1S(=O)(=O)Cl BEWITPGTUWHPDN-UHFFFAOYSA-N 0.000 description 1
- FLHLCMSUZGCCQB-UHFFFAOYSA-N 3-bromo-2,5-dimethyl-4-phenylthiophene Chemical compound BrC1=C(C)SC(C)=C1C1=CC=CC=C1 FLHLCMSUZGCCQB-UHFFFAOYSA-N 0.000 description 1
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
- RFSKGCVUDQRZSD-UHFFFAOYSA-N 3-methoxythiophene Chemical compound COC=1C=CSC=1 RFSKGCVUDQRZSD-UHFFFAOYSA-N 0.000 description 1
- FNXYWHTZDAVRTB-UHFFFAOYSA-N 3-methyl-1,2-oxazol-5-amine Chemical compound CC=1C=C(N)ON=1 FNXYWHTZDAVRTB-UHFFFAOYSA-N 0.000 description 1
- SVPMDJNGPXJCAD-UHFFFAOYSA-N 3-n,4-n-dimethyl-1,2-oxazole-3,4-diamine Chemical compound CNC1=CON=C1NC SVPMDJNGPXJCAD-UHFFFAOYSA-N 0.000 description 1
- PGXZYUWBUQWQJO-UHFFFAOYSA-N 3-phenylsulfanylthiophene-2-sulfonyl chloride Chemical compound S1C=CC(SC=2C=CC=CC=2)=C1S(=O)(=O)Cl PGXZYUWBUQWQJO-UHFFFAOYSA-N 0.000 description 1
- ZDQZVKVIYAPRON-UHFFFAOYSA-N 3-phenylthiophene Chemical compound S1C=CC(C=2C=CC=CC=2)=C1 ZDQZVKVIYAPRON-UHFFFAOYSA-N 0.000 description 1
- BMARKNAAYYILIS-UHFFFAOYSA-N 3-phenylthiophene-2-sulfonyl chloride Chemical compound S1C=CC(C=2C=CC=CC=2)=C1S(=O)(=O)Cl BMARKNAAYYILIS-UHFFFAOYSA-N 0.000 description 1
- WJYGHWXWQSCONR-UHFFFAOYSA-N 4,5-dibromothiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC(Br)=C(Br)S1 WJYGHWXWQSCONR-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- WDQGLFQJLHSSGJ-UHFFFAOYSA-N 4-bromo-3-methyl-3h-1,2-oxazol-2-amine Chemical compound CC1N(N)OC=C1Br WDQGLFQJLHSSGJ-UHFFFAOYSA-N 0.000 description 1
- JEZOZNWEHSNXPQ-UHFFFAOYSA-N 4-bromo-5-methyl-1,2-oxazol-3-amine Chemical compound CC=1ON=C(N)C=1Br JEZOZNWEHSNXPQ-UHFFFAOYSA-N 0.000 description 1
- HTAXOQIVKCKTJR-UHFFFAOYSA-N 4-bromothiophene Chemical compound BrC1=[C]SC=C1 HTAXOQIVKCKTJR-UHFFFAOYSA-N 0.000 description 1
- IMVRMHNCGCAEES-UHFFFAOYSA-N 4-bromothiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC(Br)=CS1 IMVRMHNCGCAEES-UHFFFAOYSA-N 0.000 description 1
- NVVVQTNTLIAISI-UHFFFAOYSA-N 4-butan-2-ylaniline Chemical compound CCC(C)C1=CC=C(N)C=C1 NVVVQTNTLIAISI-UHFFFAOYSA-N 0.000 description 1
- OGIQUQKNJJTLSZ-UHFFFAOYSA-N 4-butylaniline Chemical compound CCCCC1=CC=C(N)C=C1 OGIQUQKNJJTLSZ-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- JVFCCRJSBNUDDU-UHFFFAOYSA-N 4-phenylbenzenesulfonamide Chemical class C1=CC(S(=O)(=O)N)=CC=C1C1=CC=CC=C1 JVFCCRJSBNUDDU-UHFFFAOYSA-N 0.000 description 1
- NQGBGTSPIMZSGI-UHFFFAOYSA-N 5-(2-methylfuran-3-yl)thiophene-2-sulfonyl chloride Chemical compound O1C=CC(C=2SC(=CC=2)S(Cl)(=O)=O)=C1C NQGBGTSPIMZSGI-UHFFFAOYSA-N 0.000 description 1
- XZILMKNRTJQLMZ-UHFFFAOYSA-N 5-(2-methylphenyl)thiophene-2-sulfonyl chloride Chemical compound CC1=CC=CC=C1C1=CC=C(S(Cl)(=O)=O)S1 XZILMKNRTJQLMZ-UHFFFAOYSA-N 0.000 description 1
- LKJAVNDMTUOCEW-UHFFFAOYSA-N 5-(3-aminophenyl)-n-(3-methyl-1,2-oxazol-5-yl)thiophene-2-sulfonamide Chemical compound O1N=C(C)C=C1NS(=O)(=O)C1=CC=C(C=2C=C(N)C=CC=2)S1 LKJAVNDMTUOCEW-UHFFFAOYSA-N 0.000 description 1
- CXSCKHAYAHUHKW-UHFFFAOYSA-N 5-(3-methylphenyl)thiophene-2-sulfonyl chloride Chemical compound CC1=CC=CC(C=2SC(=CC=2)S(Cl)(=O)=O)=C1 CXSCKHAYAHUHKW-UHFFFAOYSA-N 0.000 description 1
- PZHAFFSEQBNUOB-UHFFFAOYSA-N 5-(4-methoxyphenyl)thiophene-2-sulfonyl chloride Chemical compound C1=CC(OC)=CC=C1C1=CC=C(S(Cl)(=O)=O)S1 PZHAFFSEQBNUOB-UHFFFAOYSA-N 0.000 description 1
- DFODBHBEWSZEMR-UHFFFAOYSA-N 5-(4-propylphenyl)thiophene-2-sulfonyl chloride Chemical compound C1=CC(CCC)=CC=C1C1=CC=C(S(Cl)(=O)=O)S1 DFODBHBEWSZEMR-UHFFFAOYSA-N 0.000 description 1
- JTJDGJXODMZCIQ-UHFFFAOYSA-N 5-(5-methylfuran-2-yl)thiophene-2-sulfonyl chloride Chemical compound O1C(C)=CC=C1C1=CC=C(S(Cl)(=O)=O)S1 JTJDGJXODMZCIQ-UHFFFAOYSA-N 0.000 description 1
- GSLVRDAYMHUGTF-UHFFFAOYSA-N 5-(benzenesulfonyl)thiophene-2-sulfonyl chloride Chemical compound S1C(S(=O)(=O)Cl)=CC=C1S(=O)(=O)C1=CC=CC=C1 GSLVRDAYMHUGTF-UHFFFAOYSA-N 0.000 description 1
- YJCKTIDJVDQPER-UHFFFAOYSA-N 5-(phenylmethoxymethyl)thiophene-2-sulfonyl chloride Chemical compound S1C(S(=O)(=O)Cl)=CC=C1COCC1=CC=CC=C1 YJCKTIDJVDQPER-UHFFFAOYSA-N 0.000 description 1
- DMIQAMZFVXKIEO-UHFFFAOYSA-N 5-benzylthiophene-2-sulfonic acid Chemical compound S1C(S(=O)(=O)O)=CC=C1CC1=CC=CC=C1 DMIQAMZFVXKIEO-UHFFFAOYSA-N 0.000 description 1
- FBOYMIDCHINJKC-UHFFFAOYSA-N 5-bromo-1,3-benzodioxole Chemical compound BrC1=CC=C2OCOC2=C1 FBOYMIDCHINJKC-UHFFFAOYSA-N 0.000 description 1
- WAKGPXGGHCIIEL-UHFFFAOYSA-N 5-bromo-n-(3,4-dimethyl-1,2-oxazol-5-yl)thiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC(Br)=CC=2)=C1C WAKGPXGGHCIIEL-UHFFFAOYSA-N 0.000 description 1
- LPXDRCXWMGEAHO-UHFFFAOYSA-N 5-bromo-n-(4-bromo-3-methyl-1,2-oxazol-5-yl)thiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC(Br)=CC=2)=C1Br LPXDRCXWMGEAHO-UHFFFAOYSA-N 0.000 description 1
- AOGQFXZYUJENDX-UHFFFAOYSA-N 5-phenylfuran-2-sulfonyl chloride Chemical compound O1C(S(=O)(=O)Cl)=CC=C1C1=CC=CC=C1.O1C(S(=O)(=O)Cl)=CC=C1C1=CC=CC=C1 AOGQFXZYUJENDX-UHFFFAOYSA-N 0.000 description 1
- JEGPQTHFTBGGGA-UHFFFAOYSA-N 5-phenylfuran-2-sulfonyl chloride Chemical compound O1C(S(=O)(=O)Cl)=CC=C1C1=CC=CC=C1 JEGPQTHFTBGGGA-UHFFFAOYSA-N 0.000 description 1
- NHRKTBLHJKMFTP-UHFFFAOYSA-N 5-phenylthiophene-2-sulfonyl chloride Chemical compound S1C(S(=O)(=O)Cl)=CC=C1C1=CC=CC=C1 NHRKTBLHJKMFTP-UHFFFAOYSA-N 0.000 description 1
- QYSCTZCCFSNPHP-UHFFFAOYSA-N 5-thiophen-2-ylthiophene-2-sulfonyl chloride Chemical compound S1C(S(=O)(=O)Cl)=CC=C1C1=CC=CS1 QYSCTZCCFSNPHP-UHFFFAOYSA-N 0.000 description 1
- WLLCBVYLKAWWNB-UHFFFAOYSA-N 5-thiophen-3-ylthiophene-2-sulfonyl chloride Chemical compound S1C(S(=O)(=O)Cl)=CC=C1C1=CSC=C1.S1C(S(=O)(=O)Cl)=CC=C1C1=CSC=C1 WLLCBVYLKAWWNB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000270279 Atractaspis Species 0.000 description 1
- VYCMAAOURFJIHD-PJNXIOHISA-N BQ 123 Chemical compound N1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(O)=O)NC(=O)[C@H]1CC1=CNC2=CC=CC=C12 VYCMAAOURFJIHD-PJNXIOHISA-N 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DZZQUTXDHJDJEF-UHFFFAOYSA-N BrC=1C(=C(C=C(C=1)C)C=1SC=CC=1)C Chemical compound BrC=1C(=C(C=C(C=1)C)C=1SC=CC=1)C DZZQUTXDHJDJEF-UHFFFAOYSA-N 0.000 description 1
- DALOIAVEMDGYJH-UHFFFAOYSA-N BrN1C(CCC1=O)=O.BrC1=CC=C(S1)C=1SC=CC1 Chemical compound BrN1C(CCC1=O)=O.BrC1=CC=C(S1)C=1SC=CC1 DALOIAVEMDGYJH-UHFFFAOYSA-N 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- RTGGTDMNWYSPGZ-UHFFFAOYSA-N C1(=CC(=CC=C1)C=1SC=CC1)C.C1(=CC(=CC=C1)C=1SC=CC1)C Chemical compound C1(=CC(=CC=C1)C=1SC=CC1)C.C1(=CC(=CC=C1)C=1SC=CC1)C RTGGTDMNWYSPGZ-UHFFFAOYSA-N 0.000 description 1
- COZPNCZALXJKQG-UHFFFAOYSA-N C1(=CC=CC=C1)C=1OC=CC1.C1(=CC=CC=C1)C=1OC=CC1 Chemical compound C1(=CC=CC=C1)C=1OC=CC1.C1(=CC=CC=C1)C=1OC=CC1 COZPNCZALXJKQG-UHFFFAOYSA-N 0.000 description 1
- XHTAVZMKDZTRFA-UHFFFAOYSA-N C1OC=2C=C(CC3=CC4=C(S3)C=CC=C4)C=CC2O1.C1OC=2C=C(CC4=CC3=C(S4)C=CC=C3)C=CC2O1 Chemical compound C1OC=2C=C(CC3=CC4=C(S3)C=CC=C4)C=CC2O1.C1OC=2C=C(CC4=CC3=C(S4)C=CC=C3)C=CC2O1 XHTAVZMKDZTRFA-UHFFFAOYSA-N 0.000 description 1
- XFEBXFGJOLOAME-UHFFFAOYSA-N CC1(N=C2C=CC=CC2=C1)S(=O)(=O)Cl.CC1(N=C2C=CC=CC2=C1)S(=O)(=O)Cl Chemical compound CC1(N=C2C=CC=CC2=C1)S(=O)(=O)Cl.CC1(N=C2C=CC=CC2=C1)S(=O)(=O)Cl XFEBXFGJOLOAME-UHFFFAOYSA-N 0.000 description 1
- 102100038460 CDK5 regulatory subunit-associated protein 3 Human genes 0.000 description 1
- RTRFVHNSNQKDEV-UHFFFAOYSA-N COC1=CC=C(N)C=C1.BrC=1C(=NOC1NS(=O)(=O)C1=C(SC=C1)C(=O)NC1=CC=C(C=C1)OC)C Chemical compound COC1=CC=C(N)C=C1.BrC=1C(=NOC1NS(=O)(=O)C1=C(SC=C1)C(=O)NC1=CC=C(C=C1)OC)C RTRFVHNSNQKDEV-UHFFFAOYSA-N 0.000 description 1
- DPKGBEFIAFYPNR-UHFFFAOYSA-N COC=1C=C(CC2=C(C3=C(S2)C=CC=C3)S(=O)(=O)Cl)C=CC1OC.COC=1C=C(CC3=C(C2=C(S3)C=CC=C2)S(=O)(=O)Cl)C=CC1OC Chemical compound COC=1C=C(CC2=C(C3=C(S2)C=CC=C3)S(=O)(=O)Cl)C=CC1OC.COC=1C=C(CC3=C(C2=C(S3)C=CC=C2)S(=O)(=O)Cl)C=CC1OC DPKGBEFIAFYPNR-UHFFFAOYSA-N 0.000 description 1
- 101100289894 Caenorhabditis elegans lys-7 gene Proteins 0.000 description 1
- 101100264074 Caenorhabditis elegans wrn-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000272470 Circus Species 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 244000182691 Echinochloa frumentacea Species 0.000 description 1
- 235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
- 230000010591 Endothelin Receptor Interactions Effects 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- TWLLPUMZVVGILS-UHFFFAOYSA-N Ethyl 2-aminobenzoate Chemical compound CCOC(=O)C1=CC=CC=C1N TWLLPUMZVVGILS-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000224421 Heterolobosea Species 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101000882982 Homo sapiens CDK5 regulatory subunit-associated protein 3 Proteins 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- 101100310662 Homo sapiens SOX21 gene Proteins 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 241000562429 Jamides Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- JVXGPPFLRUTQPD-UHFFFAOYSA-N N-(3,4-dimethyl-1,2-oxazol-5-yl)-2-[(2-hydroxyphenyl)methyl]-2-(2-trimethylsilylethoxymethyl)-3H-thiophene-3-sulfonamide Chemical compound C[Si](CCOCC1(SC=CC1S(=O)(=O)NC1=C(C(=NO1)C)C)CC1=C(C=CC=C1)O)(C)C JVXGPPFLRUTQPD-UHFFFAOYSA-N 0.000 description 1
- WVPCLXKNCMLPRO-UHFFFAOYSA-N N-(4-bromo-3-methyl-1,2-oxazol-5-yl)thiophene-3-sulfonamide Chemical compound BrC=1C(=NOC1NS(=O)(=O)C1=CSC=C1)C.BrC=1C(=NOC1NS(=O)(=O)C1=CSC=C1)C WVPCLXKNCMLPRO-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241001549389 Oreta Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034567 Peripheral circulatory failure Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- BHUIUXNAPJIDOG-UHFFFAOYSA-N Piperonol Chemical compound OCC1=CC=C2OCOC2=C1 BHUIUXNAPJIDOG-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 201000001068 Prinzmetal angina Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101100313003 Rattus norvegicus Tanc1 gene Proteins 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100035491 Ribosomal RNA small subunit methyltransferase NEP1 Human genes 0.000 description 1
- 208000036366 Sensation of pressure Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100030247 Transcription factor SOX-21 Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 241001428384 Zamora Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- ZFVDDMSKRGMPEF-UHFFFAOYSA-N [2-(2-phenylethenyl)thiophen-3-yl] acetate Chemical compound C1=CSC(C=CC=2C=CC=CC=2)=C1OC(=O)C ZFVDDMSKRGMPEF-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000005136 alkenylsulfinyl group Chemical group 0.000 description 1
- 125000005137 alkenylsulfonyl group Chemical group 0.000 description 1
- 125000005108 alkenylthio group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- QUMXDOLUJCHOAY-UHFFFAOYSA-N alpha-methylbenzyl acetate Natural products CC(=O)OC(C)C1=CC=CC=C1 QUMXDOLUJCHOAY-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 150000008331 benzenesulfonamides Chemical class 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- HZZGDPLAJHVHSP-GKHTVLBPSA-N big endothelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 HZZGDPLAJHVHSP-GKHTVLBPSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 125000005019 carboxyalkenyl group Chemical group 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000009989 contractile response Effects 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940045803 cuprous chloride Drugs 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 108010031322 cyclo(Trp-Asp-Pro-Val-Leu) Proteins 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- IBBSUPSAEOKRJQ-UHFFFAOYSA-N cyclohexyl 3-[(4-chloro-3-methyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxylate Chemical compound CC1=NOC(NS(=O)(=O)C2=C(SC=C2)C(=O)OC2CCCCC2)=C1Cl IBBSUPSAEOKRJQ-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- MBMQTRMGICAFJH-UHFFFAOYSA-N dibenzofuran-2-sulfonic acid dibenzofuran-2-sulfonyl chloride Chemical compound C1=C(C=CC=2OC3=C(C21)C=CC=C3)S(=O)(=O)O.C3=C(C=CC=2OC1=C(C23)C=CC=C1)S(=O)(=O)Cl MBMQTRMGICAFJH-UHFFFAOYSA-N 0.000 description 1
- ULCKEERECJMLHP-UHFFFAOYSA-N dibenzofuran-2-sulfonyl chloride Chemical compound C1=CC=C2C3=CC(S(=O)(=O)Cl)=CC=C3OC2=C1 ULCKEERECJMLHP-UHFFFAOYSA-N 0.000 description 1
- RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- ANCBHJKEYPZCTE-UHFFFAOYSA-N ethyl 5-carbamoyl-4-methyl-2-[(2,3,4,5,6-pentafluorobenzoyl)amino]thiophene-3-carboxylate Chemical compound CC1=C(C(N)=O)SC(NC(=O)C=2C(=C(F)C(F)=C(F)C=2F)F)=C1C(=O)OCC ANCBHJKEYPZCTE-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- PCBBEIXTVWWTAK-UHFFFAOYSA-N furan-3-sulfonyl chloride Chemical compound ClS(=O)(=O)C=1C=COC=1 PCBBEIXTVWWTAK-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- GFJCZELBSGPAPC-UHFFFAOYSA-N methyl 3-[(4-bromo-3-methyl-1,2-oxazol-5-yl)sulfamoyl]thiophene-2-carboxylate Chemical compound S1C=CC(S(=O)(=O)NC2=C(C(C)=NO2)Br)=C1C(=O)OC GFJCZELBSGPAPC-UHFFFAOYSA-N 0.000 description 1
- OSQRBRJRQUDKJB-UHFFFAOYSA-N methyl 3-pyrrol-1-ylsulfonylthiophene-2-carboxylate Chemical compound C(=O)(OC)C=1SC=CC1S(=O)(=O)N1C=CC=C1.C(=O)(OC)C=1SC=CC1S(=O)(=O)N1C=CC=C1 OSQRBRJRQUDKJB-UHFFFAOYSA-N 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 101150067960 mmoD gene Proteins 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- QCIFLGSATTWUQJ-UHFFFAOYSA-N n,4-dimethylaniline Chemical compound CNC1=CC=C(C)C=C1 QCIFLGSATTWUQJ-UHFFFAOYSA-N 0.000 description 1
- VMESOKCXSYNAKD-UHFFFAOYSA-N n,n-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
- LGGKUCGGXKJLDR-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-1-benzofuran-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2OC3=CC=CC=C3C=2)=C1C.CC1=NOC(NS(=O)(=O)C=2OC3=CC=CC=C3C=2)=C1C LGGKUCGGXKJLDR-UHFFFAOYSA-N 0.000 description 1
- UECNEXAVUODUTK-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-1-benzothiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC3=CC=CC=C3C=2)=C1C UECNEXAVUODUTK-UHFFFAOYSA-N 0.000 description 1
- XNMRLDNAICBWMW-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)-2-methyl-1-benzothiophene-3-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2C3=CC=CC=C3SC=2C)=C1C XNMRLDNAICBWMW-UHFFFAOYSA-N 0.000 description 1
- OIGDSALPIHFJLR-UHFFFAOYSA-N n-(3,4-dimethyl-1,2-oxazol-5-yl)thiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC=CC=2)=C1C OIGDSALPIHFJLR-UHFFFAOYSA-N 0.000 description 1
- VVMIQBHBYZKQJX-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-2,5-dimethylthiophene-3-sulfonamide Chemical compound S1C(C)=CC(S(=O)(=O)NC2=C(C(C)=NO2)Br)=C1C VVMIQBHBYZKQJX-UHFFFAOYSA-N 0.000 description 1
- IPZBJXVEBUKSJF-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-2-[(4-ethylphenyl)methyl]-1-benzothiophene-3-sulfonamide Chemical compound C1=CC(CC)=CC=C1CC1=C(S(=O)(=O)NC2=C(C(C)=NO2)Br)C2=CC=CC=C2S1 IPZBJXVEBUKSJF-UHFFFAOYSA-N 0.000 description 1
- SOVAQDYTHJXDHM-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-2-butyl-1-benzothiophene-3-sulfonamide Chemical compound CCCCC=1SC2=CC=CC=C2C=1S(=O)(=O)NC=1ON=C(C)C=1Br SOVAQDYTHJXDHM-UHFFFAOYSA-N 0.000 description 1
- ZZMMUCOUBOKKCX-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-2-ethyl-1-benzothiophene-3-sulfonamide Chemical compound CCC=1SC2=CC=CC=C2C=1S(=O)(=O)NC=1ON=C(C)C=1Br ZZMMUCOUBOKKCX-UHFFFAOYSA-N 0.000 description 1
- CHSJDJZZUJFWQS-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-3-phenoxythiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C2=C(C=CS2)OC=2C=CC=CC=2)=C1Br CHSJDJZZUJFWQS-UHFFFAOYSA-N 0.000 description 1
- XFFQPSUWAJAJRA-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-3-phenylsulfanylthiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C2=C(C=CS2)SC=2C=CC=CC=2)=C1Br XFFQPSUWAJAJRA-UHFFFAOYSA-N 0.000 description 1
- XEAVSGOYZRKLQG-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-3-phenylthiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C2=C(C=CS2)C=2C=CC=CC=2)=C1Br XEAVSGOYZRKLQG-UHFFFAOYSA-N 0.000 description 1
- YXNUVUBJZWQNMD-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-4,5-dichlorothiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC(Cl)=C(Cl)C=2)=C1Br YXNUVUBJZWQNMD-UHFFFAOYSA-N 0.000 description 1
- NXWRCHOPXGTIMB-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-4-phenylthiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC=C(C=2)C=2C=CC=CC=2)=C1Br NXWRCHOPXGTIMB-UHFFFAOYSA-N 0.000 description 1
- IRIFRVYDXUSKDG-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-(2-methoxyphenyl)thiophene-2-sulfonamide Chemical compound COC1=CC=CC=C1C1=CC=C(S(=O)(=O)NC2=C(C(C)=NO2)Br)S1 IRIFRVYDXUSKDG-UHFFFAOYSA-N 0.000 description 1
- DFCGTUXMYVMBCO-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-(3-methoxyphenyl)thiophene-2-sulfonamide Chemical compound COC1=CC=CC(C=2SC(=CC=2)S(=O)(=O)NC2=C(C(C)=NO2)Br)=C1 DFCGTUXMYVMBCO-UHFFFAOYSA-N 0.000 description 1
- LMAWWMNLFLJRON-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-(3-methylphenyl)thiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC(=CC=2)C=2C=C(C)C=CC=2)=C1Br LMAWWMNLFLJRON-UHFFFAOYSA-N 0.000 description 1
- FNEYKGWJPZVVJQ-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-(4-ethylphenyl)thiophene-2-sulfonamide Chemical compound C1=CC(CC)=CC=C1C1=CC=C(S(=O)(=O)NC2=C(C(C)=NO2)Br)S1 FNEYKGWJPZVVJQ-UHFFFAOYSA-N 0.000 description 1
- CBEXVLRGVGAGJY-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-(4-propan-2-ylphenyl)thiophene-2-sulfonamide Chemical compound C1=CC(C(C)C)=CC=C1C1=CC=C(S(=O)(=O)NC2=C(C(C)=NO2)Br)S1 CBEXVLRGVGAGJY-UHFFFAOYSA-N 0.000 description 1
- UVFCRBPIDXVPDP-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-(phenylmethoxymethyl)thiophene-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC(COCC=3C=CC=CC=3)=CC=2)=C1Br UVFCRBPIDXVPDP-UHFFFAOYSA-N 0.000 description 1
- BSSVSEIIJDBNTN-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-phenylfuran-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2OC(=CC=2)C=2C=CC=CC=2)=C1Br BSSVSEIIJDBNTN-UHFFFAOYSA-N 0.000 description 1
- LCZZTDNACDGWMX-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-phenylfuran-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2OC(=CC=2)C=2C=CC=CC=2)=C1Br.CC1=NOC(NS(=O)(=O)C=2OC(=CC=2)C=2C=CC=CC=2)=C1Br LCZZTDNACDGWMX-UHFFFAOYSA-N 0.000 description 1
- VNPNFUCBRHWANV-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)-5-phenylsulfanylfuran-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2OC(SC=3C=CC=CC=3)=CC=2)=C1Br VNPNFUCBRHWANV-UHFFFAOYSA-N 0.000 description 1
- DJXXKTFTUVBUJY-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)furan-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2OC=CC=2)=C1Br DJXXKTFTUVBUJY-UHFFFAOYSA-N 0.000 description 1
- DYJPRYOZZBRIGG-UHFFFAOYSA-N n-(4-bromo-3-methyl-1,2-oxazol-5-yl)thiophene-3-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C2=CSC=C2)=C1Br DYJPRYOZZBRIGG-UHFFFAOYSA-N 0.000 description 1
- BGEOYNNWNRFHSR-UHFFFAOYSA-N n-(4-chloro-3-methyl-1,2-oxazol-5-yl)-1,3-thiazole-2-sulfonamide Chemical compound CC1=NOC(NS(=O)(=O)C=2SC=CN=2)=C1Cl BGEOYNNWNRFHSR-UHFFFAOYSA-N 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- JHLLSPONPZPHIX-UHFFFAOYSA-N n-(pyran-2-ylideneamino)benzenesulfonamide Chemical class C=1C=CC=CC=1S(=O)(=O)NN=C1C=CC=CO1 JHLLSPONPZPHIX-UHFFFAOYSA-N 0.000 description 1
- GUOONOJYWQOJJP-DCMFLLSESA-N n-[(2s,3r)-3-hydroxy-1-phenyl-4-[[3-(trifluoromethoxy)phenyl]methylamino]butan-2-yl]-3-[methyl(methylsulfonyl)amino]-5-[(2r)-2-(4-methyl-1,3-thiazol-2-yl)pyrrolidine-1-carbonyl]benzamide Chemical compound C1([C@H]2CCCN2C(=O)C=2C=C(C=C(C=2)N(C)S(C)(=O)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)[C@H](O)CNCC=2C=C(OC(F)(F)F)C=CC=2)=NC(C)=CS1 GUOONOJYWQOJJP-DCMFLLSESA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ZFIFHAKCBWOSRN-UHFFFAOYSA-N naphthalene-1-sulfonamide Chemical class C1=CC=C2C(S(=O)(=O)N)=CC=CC2=C1 ZFIFHAKCBWOSRN-UHFFFAOYSA-N 0.000 description 1
- HKGOFWIZZIYCOS-UHFFFAOYSA-N naphthalene-2-sulfonic acid;hydrate Chemical compound O.C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 HKGOFWIZZIYCOS-UHFFFAOYSA-N 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- LRTFPLFDLJYEKT-UHFFFAOYSA-N para-isopropylaniline Chemical compound CC(C)C1=CC=C(N)C=C1 LRTFPLFDLJYEKT-UHFFFAOYSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000009090 positive inotropic effect Effects 0.000 description 1
- 230000000063 preceeding effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229960001544 sulfathiazole Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- ZPHGMBGIFODUMF-UHFFFAOYSA-N thiophen-2-ylmethanol Chemical compound OCC1=CC=CS1 ZPHGMBGIFODUMF-UHFFFAOYSA-N 0.000 description 1
- JBWPAMVNJXDNOH-UHFFFAOYSA-N thiophen-3-ylmethylboronic acid Chemical compound OB(O)CC=1C=CSC=1 JBWPAMVNJXDNOH-UHFFFAOYSA-N 0.000 description 1
- VNNLHYZDXIBHKZ-UHFFFAOYSA-N thiophene-2-sulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CS1 VNNLHYZDXIBHKZ-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 101150079396 trpC2 gene Proteins 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41619995A | 1995-04-04 | 1995-04-04 | |
| US41707595A | 1995-04-04 | 1995-04-04 | |
| US08/477,223 US5594021A (en) | 1993-05-20 | 1995-06-06 | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA10621A true OA10621A (en) | 2001-03-16 |
Family
ID=27411089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA70095A OA10621A (en) | 1995-04-04 | 1997-10-02 | Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1048657A1 (hu) |
| JP (3) | JP3233642B2 (hu) |
| KR (2) | KR100359396B1 (hu) |
| CN (1) | CN1130355C (hu) |
| AT (1) | ATE243203T1 (hu) |
| AU (1) | AU711968B2 (hu) |
| CA (1) | CA2217169C (hu) |
| CZ (1) | CZ299246B6 (hu) |
| DE (2) | DE122006000068I1 (hu) |
| DK (1) | DK0819125T3 (hu) |
| EA (2) | EA007107B1 (hu) |
| EE (1) | EE9700251A (hu) |
| ES (1) | ES2201181T3 (hu) |
| FI (1) | FI973879A0 (hu) |
| HK (1) | HK1001769A1 (hu) |
| HU (1) | HUP9802034A3 (hu) |
| NL (1) | NL300251I2 (hu) |
| NO (1) | NO315607B1 (hu) |
| NZ (2) | NZ500282A (hu) |
| OA (1) | OA10621A (hu) |
| PL (1) | PL186854B1 (hu) |
| PT (1) | PT819125E (hu) |
| TR (1) | TR199701096T1 (hu) |
| TW (1) | TW492966B (hu) |
| WO (1) | WO1996031492A1 (hu) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962490A (en) * | 1987-09-25 | 1999-10-05 | Texas Biotechnology Corporation | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US6541498B2 (en) | 1993-05-20 | 2003-04-01 | Texas Biotechnology | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6030991A (en) * | 1993-05-20 | 2000-02-29 | Texas Biotechnology Corp. | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6376523B1 (en) | 1994-05-20 | 2002-04-23 | Texas Biotechnology Corporation | Benzenesulfonamides and the use thereof to modulate the activity of endothelin |
| US6613804B2 (en) | 1993-05-20 | 2003-09-02 | Encysive Pharmaceuticals, Inc. | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
| CZ263098A3 (cs) | 1996-02-20 | 1999-05-12 | Bristol-Myers Squibb Company | Způsoby přípravy bifenylisoxazolsulfonamidů |
| US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
| US5804585A (en) * | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
| WO1998033781A1 (en) * | 1997-01-30 | 1998-08-06 | Bristol-Myers Squibb Company | Method for preventing or treating low renin hypertension by administering an endothelin antagonist |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US5783705A (en) * | 1997-04-28 | 1998-07-21 | Texas Biotechnology Corporation | Process of preparing alkali metal salys of hydrophobic sulfonamides |
| CA2281090C (en) * | 1997-04-28 | 2005-06-07 | Texas Biotechnology Corporation | Sulfonamide compounds and salts for treatment of endothelin-mediated disorders |
| GB9716657D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| GB9803228D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| GB9803226D0 (en) | 1998-02-17 | 1998-04-08 | Zeneca Ltd | Chemical compounds |
| KR20010083092A (ko) * | 1998-07-06 | 2001-08-31 | 스티븐 비. 데이비스 | 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드 |
| WO2000002851A1 (en) | 1998-07-08 | 2000-01-20 | Aventis Pharma Deutschland Gmbh | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| GB9902452D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902455D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902461D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| GB9902453D0 (en) | 1999-02-05 | 1999-03-24 | Zeneca Ltd | Chemical compounds |
| DE60045033D1 (de) * | 1999-08-06 | 2010-11-11 | Takeda Pharmaceutical | Substituierte aromatische ringverbindungen, verfahren zu ihrer herstellung und ihre anwendung |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| AU2456701A (en) * | 1999-12-31 | 2001-07-16 | Texas Biotechnology Corporation | Pharmaceutical and veterinary uses of endothelin antagonists |
| EP1533311B1 (en) * | 1999-12-31 | 2007-04-25 | Encysive Pharmaceuticals, Inc | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| ES2285334T3 (es) * | 1999-12-31 | 2007-11-16 | Encysive Pharmaceuticals, Inc | Sulfonamidas y sus derivados como moduladores de la actividad de endotelina. |
| GB0000625D0 (en) | 2000-01-13 | 2000-03-01 | Zeneca Ltd | Chemical compounds |
| CN1245400C (zh) * | 2000-09-18 | 2006-03-15 | 东亚荣养株式会社 | N－取代苯并噻唑磺胺衍生物 |
| US7071220B2 (en) | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| JP4155561B2 (ja) * | 2000-12-26 | 2008-09-24 | 国立大学法人佐賀大学 | アレルギー性疾患検査方法 |
| WO2003078419A1 (en) * | 2002-03-15 | 2003-09-25 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivative |
| US20060128783A1 (en) * | 2002-08-09 | 2006-06-15 | Dinsmore Christopher J | Tyrosine kinase inhibitors |
| ATE482938T1 (de) | 2002-08-09 | 2010-10-15 | Merck Sharp & Dohme | Tyrosinkinaseinhibitoren |
| SE0301885D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use IV |
| SE0301884D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use III |
| SE0301883D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use II |
| SE0301888D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use VII |
| SE0301882D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use I |
| SE0301886D0 (sv) * | 2003-06-25 | 2003-06-25 | Biovitrum Ab | New use V |
| EP2439203B1 (en) * | 2004-10-14 | 2014-11-19 | AbbVie Deutschland GmbH & Co KG | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| AU2008237062A1 (en) | 2007-04-10 | 2008-10-16 | Auspex Pharmaceuticals, Inc. | Substituted deuterium enriched thiophenes for the treatment of hypertension |
| ES2601856T3 (es) | 2007-06-08 | 2017-02-16 | Mannkind Corporation | Inhibidores de la IRE-1A |
| US8592470B2 (en) | 2012-01-31 | 2013-11-26 | Eisai R&D Management Co., Ltd. | Sitaxentan derivative |
| CN107652246B (zh) * | 2017-09-25 | 2020-08-25 | 江苏乾元生物科技有限公司 | 一种3-[3-溴-2-甲基-6-(甲基磺酰基)苯基]-4,5-二氢化异噁唑的制备方法 |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| HRP20231501T1 (hr) | 2019-06-18 | 2024-03-01 | Pfizer Inc. | Derivati benzizoksazolsulfonamida |
| EP3831940A1 (en) * | 2019-12-05 | 2021-06-09 | Danmarks Tekniske Universitet | Small molecule inhibitors of crispr-cas associated activity |
| CN112663077B (zh) * | 2021-01-11 | 2022-07-01 | 陕西师范大学 | 一种苯并磺内酰胺类化合物的电化学制备方法 |
| JPWO2022270487A1 (hu) | 2021-06-22 | 2022-12-29 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3660383A (en) * | 1968-08-14 | 1972-05-02 | Shionogi & Co | Production of iodoisoxazole compounds |
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| TW224462B (hu) * | 1992-02-24 | 1994-06-01 | Squibb & Sons Inc | |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| IL116916A (en) * | 1995-02-06 | 2000-09-28 | Bristol Myers Squibb Co | Substituted biphenyl sulfonamide derivatives and pharmaceutical compositions containing the same |
-
1996
- 1996-04-04 KR KR1019970707078A patent/KR100359396B1/ko not_active IP Right Cessation
- 1996-04-04 JP JP53052496A patent/JP3233642B2/ja not_active Expired - Lifetime
- 1996-04-04 EP EP00113076A patent/EP1048657A1/en not_active Withdrawn
- 1996-04-04 TR TR97/01096T patent/TR199701096T1/xx unknown
- 1996-04-04 DE DE1996628740 patent/DE122006000068I1/de active Pending
- 1996-04-04 DK DK96912600T patent/DK0819125T3/da active
- 1996-04-04 AU AU55367/96A patent/AU711968B2/en not_active Ceased
- 1996-04-04 PT PT96912600T patent/PT819125E/pt unknown
- 1996-04-04 WO PCT/US1996/004759 patent/WO1996031492A1/en active IP Right Grant
- 1996-04-04 AT AT96912600T patent/ATE243203T1/de active
- 1996-04-04 CN CN96193973A patent/CN1130355C/zh not_active Expired - Fee Related
- 1996-04-04 EA EA199700208A patent/EA007107B1/ru not_active IP Right Cessation
- 1996-04-04 KR KR1019997007068A patent/KR100359397B1/ko not_active IP Right Cessation
- 1996-04-04 DE DE69628740T patent/DE69628740T2/de not_active Expired - Lifetime
- 1996-04-04 EA EA199900808A patent/EA199900808A1/ru unknown
- 1996-04-04 EP EP96912600A patent/EP0819125B1/en not_active Expired - Lifetime
- 1996-04-04 CZ CZ0311697A patent/CZ299246B6/cs not_active IP Right Cessation
- 1996-04-04 EE EE9700251A patent/EE9700251A/xx unknown
- 1996-04-04 CA CA002217169A patent/CA2217169C/en not_active Expired - Fee Related
- 1996-04-04 NZ NZ500282A patent/NZ500282A/xx unknown
- 1996-04-04 HU HU9802034A patent/HUP9802034A3/hu unknown
- 1996-04-04 ES ES96912600T patent/ES2201181T3/es not_active Expired - Lifetime
- 1996-04-04 NZ NZ306734A patent/NZ306734A/en unknown
- 1996-10-04 TW TW085112218A patent/TW492966B/zh not_active IP Right Cessation
-
1997
- 1997-10-01 PL PL96322707A patent/PL186854B1/pl not_active IP Right Cessation
- 1997-10-02 OA OA70095A patent/OA10621A/en unknown
- 1997-10-03 FI FI973879A patent/FI973879A0/fi not_active Application Discontinuation
- 1997-10-03 NO NO19974577A patent/NO315607B1/no not_active IP Right Cessation
-
1998
- 1998-02-05 HK HK98100844A patent/HK1001769A1/xx not_active IP Right Cessation
-
2001
- 2001-06-06 JP JP2001171692A patent/JP3527217B2/ja not_active Expired - Fee Related
-
2003
- 2003-09-10 JP JP2003318261A patent/JP2004043495A/ja active Pending
-
2006
- 2006-12-13 NL NL300251C patent/NL300251I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA10621A (en) | Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | |
| US5962490A (en) | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | |
| US5594021A (en) | Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin | |
| AU749167B2 (en) | Sulfonamides for treatment of endothelin-mediated disorders | |
| RU2151144C1 (ru) | Сульфонамиды, фармацевтическая композиция на их основе, способ лечения эндотелин-зависимых заболеваний, способ ингибирования связывания эндотелинового пептида с эндотелин a-(етa) или b-(етb) рецепторами, способ изменения вызываемой эндотелиновыми рецепторами активности. | |
| US6248767B1 (en) | Formulation of sulfonamides for treatment of endothelin-mediated disorders | |
| US6613804B2 (en) | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | |
| US6342610B2 (en) | N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | |
| CA2288439C (en) | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | |
| AU726595B2 (en) | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | |
| AU691813C (en) | Sulfonamides and derivatives thereof that modulate the activity of endothelin | |
| AU724575B2 (en) | Sulfonamides and derivatives thereof that modulate the activity of endothelin | |
| CA2420614A1 (en) | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |